The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars.
作者信息
Mazzoni Davide, Vener Claudia, Mazzocco Ketti, Monzani Dario, Pravettoni Gabriella
机构信息
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology IRCCS, Milan, Italy.
出版信息
Front Psychol. 2021 Jan 27;12:605643. doi: 10.3389/fpsyg.2021.605643. eCollection 2021.
Abstract
摘要
相似文献
1
The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars.从生物制剂非医疗性转换为生物类似药所带来的心理风险。
Front Psychol. 2021 Jan 27;12:605643. doi: 10.3389/fpsyg.2021.605643. eCollection 2021.
2
The Clinical Implications of Nocebo Effects for Biosimilar Therapy.无安慰剂效应在生物类似药治疗中的临床意义。
Front Pharmacol. 2019 Nov 29;10:1372. doi: 10.3389/fphar.2019.01372. eCollection 2019.
3
Biosimilars: complements and comments on the recent statement of the SFR and CRI. Comment on: "Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)." Schaeverbeke et al. Joint Bone Spine 2018;95:399-402.生物类似药：对法国风湿病学会（SFR）和炎性风湿病俱乐部（CRI）近期声明的补充与评论。评论内容：“生物类似药：一个机遇。法国风湿病学会（SFR）和炎性风湿病俱乐部（CRI）的立场声明”。舍韦贝克等人。《关节与脊柱》2018年；95：399 - 402。
Joint Bone Spine. 2019 Mar;86(2):287-288. doi: 10.1016/j.jbspin.2018.10.009. Epub 2018 Oct 27.
4
The nocebo effect: a clinical challenge in the era of biosimilars.安慰剂效应：生物类似药时代的临床挑战。
Expert Rev Clin Immunol. 2018 Sep;14(9):739-749. doi: 10.1080/1744666X.2018.1512406. Epub 2018 Aug 30.
5
Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.风湿领域中患者对生物类似药的信息和看法：一项法国全国性调查。
Joint Bone Spine. 2019 Jul;86(4):491-496. doi: 10.1016/j.jbspin.2019.01.001. Epub 2019 Jan 16.
6
Biosimilars in oncology: from development to clinical practice.肿瘤学中的生物类似药：从研发到临床实践。
Semin Oncol. 2014 Apr;41 Suppl 3:S3-S12. doi: 10.1053/j.seminoncol.2014.03.008. Epub 2014 Mar 13.
7
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.风湿病学中生物类似药疗法及生物制品预期仿制药的临床与监管视角
Rheumatol Int. 2016 May;36(5):613-25. doi: 10.1007/s00296-016-3444-0. Epub 2016 Feb 27.
8
Biosimilars for the treatment of psoriasis.用于治疗银屑病的生物类似药。
Expert Opin Biol Ther. 2019 Oct;19(10):993-1000. doi: 10.1080/14712598.2019.1636963. Epub 2019 Jul 1.
9
Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.包含从原研药转换为生物类似药的研究中的药物停药：系统文献回顾。
Clin Ther. 2019 Jan;41(1):155-173.e13. doi: 10.1016/j.clinthera.2018.11.002. Epub 2018 Dec 11.
10
DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.生物类似药转换为参照生物制剂后炎症性肠病患者停药率：系统评价和荟萃分析。
Arq Gastroenterol. 2020 Jul-Sep;57(3):232-243. doi: 10.1590/S0004-2803.202000000-45.
引用本文的文献
1
Stakeholder perspectives on the sustainability of the United States biosimilars market.利益相关者对美国生物类似药市场可持续性的看法。
J Manag Care Spec Pharm. 2024 Oct;30(10):1065-1072. doi: 10.18553/jmcp.2024.24104. Epub 2024 Jul 16.
2
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.《海湾地区炎症性关节炎生物类似药治疗应用的共识性总体原则和推荐意见》。
BioDrugs. 2024 May;38(3):449-463. doi: 10.1007/s40259-023-00642-1. Epub 2024 Feb 25.
本文引用的文献
1
One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology.在促进风湿病学共同决策的背景下，从原研依那西普转换为生物类似药后的一年结果。
Rheumatol Adv Pract. 2020 Aug 6;4(2):rkaa042. doi: 10.1093/rap/rkaa042. eCollection 2020.
2
Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.从参照生物制剂转换为生物类似药的非干预性研究的方法学考虑因素。
Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):757-769. doi: 10.1002/pds.4809. Epub 2019 Jul 12.
3
The non-medical switching of prescription medications.非医疗用途处方药的转换。
Postgrad Med. 2019 Jun;131(5):335-341. doi: 10.1080/00325481.2019.1618195. Epub 2019 May 29.
4
Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies.护士在帮助炎症性肠病患者过渡到生物类似药方面发挥着关键作用：教育和沟通策略。
J Crohns Colitis. 2019 Feb 1;13(2):259-266. doi: 10.1093/ecco-jcc/jjy150.
5
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.转换药物时的非药物效应：从原创药到生物类似药转换时的反安慰剂效应。
BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.
6
The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.《生物类似药的反安慰剂效应？双盲与开放标签研究的系统评价》
J Manag Care Spec Pharm. 2018 Oct;24(10):952-959. doi: 10.18553/jmcp.2018.24.10.952.
7
Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects.安慰剂和反安慰剂效应的心理生物学机制：改善治疗方法和减少副作用的途径。
Annu Rev Psychol. 2019 Jan 4;70:599-625. doi: 10.1146/annurev-psych-010418-102907. Epub 2018 Aug 15.
8
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.生物类似药的治疗效果：谨防反安慰剂效应。
Rheumatol Ther. 2017 Dec;4(2):209-218. doi: 10.1007/s40744-017-0085-z. Epub 2017 Oct 14.
9
Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland.评估医疗保健专业人员对生物类似药使用的认知和态度：对爱尔兰医生和药剂师的一项调查。
Regul Toxicol Pharmacol. 2017 Aug;88:252-261. doi: 10.1016/j.yrtph.2017.06.013. Epub 2017 Jun 27.
10
Value as the key concept in the health care system: how it has influenced medical practice and clinical decision-making processes.价值作为医疗保健系统中的关键概念：它如何影响医疗实践和临床决策过程。
J Multidiscip Healthc. 2017 Mar 21;10:101-106. doi: 10.2147/JMDH.S122383. eCollection 2017.
Zotero 插件